In-vitro targeted alpha-particle therapy (TAT) with 213Bi-Cetuximab outperforms X-Ray irradiation independent of HPV status of HNSCC cell lines - Siegl, M; Seidl, C; Bruchertseifer, F; Morgenstern, A; Zissler, U; Multhoff, G; Wollenberg, B; Pickhard, A (Laryngo-Rhino-Otologie, 2020)